The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Managing toxicity post-CAR-T therapy in multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on managing toxicities arising after CAR-T therapy in patients with multiple myeloma. Dr Lin explains that real-world data has shown that toxicities observed in clinical practice are similar to those reported in clinical trials and that clinicians are able to safely manage acute toxicities such as cytokine release syndrome (CRS) and neurological events. Nevertheless, it is important to learn how to monitor and manage rare but potentially fatal CAR-T-related adverse events, as well as late-onset neurological symptoms. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
